Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q2 2016 · 10-Q
Revenue—
Net Income$4.64M$4.64MN/M vs Q2 2015 EPS Diluted-$0.17-$0.17N/M vs Q2 2015 Operating Income$4,671,235N/M Operating Cash Flowderived-$5,165,493N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,165,493N/M ended Jun 30, 2016 · filed Aug 9, 2016 · 40 d after period end